Patients with underlying skin disease or recurring cellulitis were more likely to fail initial antibiotic therapy.
More than 3% of U.S. emergency department (ED) visits are for skin infections, and about four out of five of these are cellulitis rather than abscess. Most patients with cellulitis are treated as outpatients, but prior research suggests that treatment is often unsuccessful.
Investigators studied predictors of treatment failure in patients with cellulitis receiving outpatient treatment at two Canadian academic EDs. Full follow-up was available for 499 patients, of whom 21% failed therapy (they required different antibiotics or hospital admission). Predictors of treatment failure were temperature >38°C at triage (odds ratio, 4.3), chronic leg ulcers (OR, 2.5), chronic edema or lymphedema (OR, 2.5), prior cellulitis in the same area (OR, 2.1), …
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals